MSF Field Research > 1 Published Research and Commentary > Other Diseases > CMV retinitis in China and SE Asia: the way forward

Please use this identifier to cite or link to this item: http://hdl.handle.net/10144/213250
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!


Download this article:
View/Open File Description Size Format
Thumbnail
View/Open
111124_Heiden_CMV-retinitis-in-China-and-SE-Asia_BMC-Infect-Dis-11-327.pdf185KbAdobe PDF

Title: CMV retinitis in China and SE Asia: the way forward
Authors: Heiden, David
Saranchuk, Peter
Affiliation: Department of Ophthalmology, California Pacific Medical Center, San Francisco, CA, USA; Seva Foundation, Berkeley, CA, USA; South African Medical Unit, Operational Centre Brussels, Medicines Sans Frontieres, Cape Town, South Africa
Citation: BMC Infectious Diseases 2011; 11:327
Publisher: BioMed Central
Journal: BMC Infectious Diseases
Issue Date: 24-Nov-2011
URI: http://hdl.handle.net/10144/213250
DOI: 10.1186/1471-2334-11-327
Additional Links: http://www.biomedcentral.com/1471-2334/11/327
Abstract: AIDS-related CMV retinitis is a common clinical problem in patients with advanced HIV/AIDS in China and Southeast Asia. The disease is causing blindness, and current clinical management, commonly characterized by delayed diagnosis and inadequate treatment, results in poor clinical outcomes: 21% - 36% of eyes with CMV retinitis are already blind at the time the diagnosis is first established by an ophthalmologist. CMV retinitis also identifies a group of patients at extraordinary risk of mortality, and the direct or indirect contribution of extraocular CMV disease to AIDS-related morbidity and mortality is currently unmeasured and clinically often overlooked. The obvious way to improve clinical management of CMV retinitis is to screen all patients with CD4 counts < 100 cells/μL with indirect ophthalmoscopy at the time they first present for care, and to provide systemic treatment with oral valganciclovir when active CMV retinitis is detected. Treatment of opportunistic infections is an integral part of HIV management, and, with appropriate training and support, CMV retinitis screening and treatment can be managed by the HIV clinicians, like all other opportunistic infections. Access to ophthalmologist has been problematic for HIV patients in China, and although non-ophthalmologists can perform screening, sophisticated ophthalmological skills are required for the management of retinal detachment and immune recovery uveitis, the major complications of CMV retinitis. CMV retinitis has been clinically ignored, in part, because of the perceived complexity and expense of treatment, and this obstacle can be removed by making valganciclovir affordable and widely available. Valganciclovir is an essential drug for developing successful programs for management of CMV retinitis in China and throughout SE Asia.
Type: Article
Language: en
MeSH: Cytomegalovirus retinitis
Eye diseases
ISSN: 1471-2334
Rights: Archived with thanks to BMC Infectious Diseases
Appears in topics: Other Diseases

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.

 

OR Logo Powered by Open Repository | Cookies

My MSF

MSF logo MSF Field Research

Dec 18, 2014